First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV Negative Women
Reported by Jules Levin
Pharmacology Workshop April 2009
Amanda E Jones, Jasmine A Talameh, Kristine B Patterson, Nazer L Rezk, Heather A Prince, and
Angela DM Kashuba
University of North Carolina
Chapel Hill, NC, USA
**Supported in part by a research grant from the Investigator-Initiated Studies Program of Merck & Co., Inc. The opinions expressed in this presentation are those of the authors and do not necessarily represent those of Merck & Co., Inc.**
